English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Effects of  UGT1A1 *6 and  UGT1A1 *28 genetic polymorphisms on irinotecan‐induced severe toxicities in Asian cancer patients are inconclusive. Also,  ABCC2 c.3972C&gt;T  may affect toxicity of irinotecan. The aim was to assess the aggregated risk of neutropenia or diarrhea in Asian cancer patients taking irinotecan and inherited  UGT1A1*6 ,  UGT1A1*28,  or  ABCC2 c.3972C&gt;T  genetic variants. A PubMed literature search for eligible studies was conducted. Odds ratios (ORs) were measured using RevMan software where  p  values &lt;0.05 were statistically significant. Patients that inherited both  UGT1A1*6  and  UGT1A1*28  genetic variants (heterozygous:  UGT1A1*1/*6  +  *1/*28  and homozygous:  UGT1A1*6/*6  +  *28/*28 ) were significantly associated with increased risk of neutropenia and diarrhea compared to patients with  UGT1A1*1/*1  (neutropenia: OR 2.89; 95% CI 1.97–4.23;  p  &lt; 0.00001; diarrhea: OR 2.26; 95% CI 1.71–2.99;  p  &lt; 0.00001). Patients carrying homozygous variants had much stronger effects in developing toxicities (neutropenia: OR 6.23; 95% CI 3.11–12.47;  p  &lt; 0.00001; diarrhea: OR 3.21; 95% CI 2.13–4.85;  p  &lt; 0.00001) than those with heterozygous variants. However, patients carrying the  ABCC2 c.3972C&gt;T  genetic variant were not significantly associated with neutropenia (OR 1.67; 95% CI 0.98–2.84;  p  = 0.06) and were significantly associated with a reduction in irinotecan‐induced diarrhea (OR 0.31; 95% CI 0.11–0.81;  p  = 0.02). Asian cancer patients should undergo screening for both  UGT1A1*6  and  UGT1A1*28  genetic variants to reduce substantially irinotecan‐induced severe toxicities.

clinical and translational science

Association of  UGT1A1*6 ,  UGT1A1*28 , or  ABCC2 c.3972C&gt;T  genetic polymorphisms with irinotecan‐induced toxicity in Asian cancer patients: Meta‐analysis